Rare tumors are addicted to single activated oncogenes, recently exemplified by bcr-abl in CML, ALK in 4% of NSCLC, and BRAF in certain melanomas [1]–[4], [24], [29]. Here, ALK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.